Long-term Efficacy and Safety, Including COVID-19 Infections, Among Ozanimod-Treated Patients With Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial

被引：0
|
作者：
Cree, B. A. [1 ]
Selmaj, K. W. [2 ]
Steinman, L. [3 ]
Comi, G. [4 ]
Bar-Or, A. [5 ]
Arnold, D. L. [6 ]
Hartung, H. [7 ,8 ,9 ]
Montalban, X. [10 ]
Havrdova, E. K. [11 ,12 ]
Sheffield, J. K. [13 ]
Minton, N. [13 ]
Cheng, C. [13 ]
Silva, D. [13 ]
Kappos, L. [14 ,15 ,16 ,17 ,18 ]
Cohen, J. A. [19 ]
机构：
[1] Weill Inst Neurosci, San Francisco, CA USA
[2] Univ Warmia & Mazury, Ctr Neurol & Coll Med, Lodz, Poland
[3] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Med Ctr, Stanford, CA 94305 USA
[4] Vita Salute San Raffaele Univ & Casa Cura Policli, Milan, Italy
[5] McGill Univ, Philadelphia, PA USA
[6] Montreal Neurol Inst, Neurol & Neurosurg, Montreal, PQ, Canada
[7] Heinrich Heine Univ, Fac Med, Dept Neurol, Dusseldorf, Germany
[8] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia
[9] Med Univ Vienna, Dept Neurol, Dusseldorf, Germany
[10] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr dEsclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[11] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[12] Charles Univ Prague, Med Fac 1, Ctr Clin Neurosci, Prague, Czech Republic
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Univ Hosp, Dept Med, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[15] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[16] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[17] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[18] Univ Basel, Basel, Switzerland
[19] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P142
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [41] Long-term open-label treatment with Sativex® in patients with multiple sclerosis
    Constantinescu, C. S.
    Sarantis, N.
    MULTIPLE SCLEROSIS, 2006, 12 : S111 - S111
  • [42] Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study
    Gold, Ralf
    Radue, Ernst-Wilhelm
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva Kubala
    Montalban, Xavier
    Stefoski, Dusan
    Sprenger, Till
    Robinson, Randy R.
    Fam, Sami
    Smith, Jonathan
    Chalkias, Spyros
    Giannattasio, Giorgio
    Lima, Gabriel
    Castro-Borrero, Wanda
    JOURNAL OF NEUROLOGY, 2020, 267 (10) : 2851 - 2864
  • [43] Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
    Serpell, Michael G.
    Notcutt, William
    Collin, Christine
    JOURNAL OF NEUROLOGY, 2013, 260 (01) : 285 - 295
  • [44] Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
    Michael G. Serpell
    William Notcutt
    Christine Collin
    Journal of Neurology, 2013, 260 : 285 - 295
  • [45] Long-term efficacy and safety of ocrelizumab in treatment-naive patients with early relapsing multiple sclerosis: 7-year data from the OPERA open-label extension trials
    Cerqueira, J.
    Berthele, A.
    Cree, B.
    Filippi, M.
    Pardo, G.
    Pearson, O.
    Trabloulsee, A.
    Ziemssen, T.
    Vollmer, T.
    Bernasconi, C.
    Mandel, C.
    Overell, J.
    Havrdova, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 634 - 635
  • [46] Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial
    Thiele, Elizabeth A.
    Bebin, E. Martina
    Filloux, Francis
    Kwan, Patrick
    Loftus, Rachael
    Sahebkar, Farhad
    Sparagana, Steven
    Wheless, James
    EPILEPSIA, 2022, 63 (02) : 426 - 439
  • [47] Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
    Hauser, Stephen L.
    Zielman, Ronald
    Das Gupta, Ayan
    Xi, Jing
    Stoneman, Dee
    Karlsson, Goeril
    Robertson, Derrick
    Cohen, Jeffrey A.
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (11-12) : 1452 - 1464
  • [48] Impact of Ozanimod on Absolute Lymphocyte Count Stability and Recovery Over Time in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Selmaj, Krzysztof
    Cree, Bruce A. C.
    Cohen, Jeffrey
    Hartung, Hans-Peter
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Harris, Sarah
    Thorpe, Andrew
    Bar-Or, Amit
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1004 - 1004
  • [49] Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
    Gevaert, Philippe
    Saenz, Rebecca
    Corren, Jonathan
    Han, Joseph K.
    Mullol, Joaquim
    Lee, Stella E.
    Ow, Randall A.
    Zhao, Rui
    Howard, Monet
    Wong, Kit
    Islam, Lutaf
    Ligueros-Saylan, Monica
    Omachi, Theodore A.
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 957 - +
  • [50] Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
    Patel, Anup D.
    Mazurkiewicz-Beldzinska, Maria
    Chin, Richard F.
    Gil-Nagel, Antonio
    Gunning, Boudewijn
    Halford, Jonathan J.
    Mitchell, Wendy
    Scott Perry, Michael
    Thiele, Elizabeth A.
    Weinstock, Arie
    Dunayevich, Eduardo
    Checketts, Daniel
    Devinsky, Orrin
    EPILEPSIA, 2021, 62 (09) : 2228 - 2239
12345